Candida endocarditis complicating transapical aortic valve implantation.
نویسندگان
چکیده
2009;158:881–886. 21. Eikelboom JW, Mehta SR, Fox KA, Pogue J, Yusuf S. Efficacy and safety of clopidogrel in acute coronary syndrome patients at high risk of bleeding: Data from the CURE trial (abstract). Circulation 2008;118:S916. 22. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial– phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1–11. 23. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256–265. 24. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J 2005;149:227–233. 25. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627–635. 26. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599–605. 27. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008;156: 1080–1088.
منابع مشابه
Images and Case Reports in Interventional Cardiology Thrombotic Aortic Restenosis After Transapical Sapien Valve Implantation
A 78-year-old man at high risk for aortic valve replacement (Euroscore, 44%; left ventricular ejection fraction, 30%; previous bypass graft surgery) had undergone a transapical aortic valve implantation (26-mm Edwards Sapien) with a good immediate clinical and echocardiographic outcome: peak transvalvular gradient, 15 mm Hg; aortic valve area, 1.6 cm; and trivial aortic regurgitation (Figure 1)...
متن کاملInitial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation.
OBJECTIVES This analysis reports on the initial German multicenter experience with the JenaValve (JenaValve Technology GmbH, Munich, Germany) transcatheter heart valve for the treatment of pure aortic regurgitation. BACKGROUND Experience with transcatheter aortic valve implantation (TAVI) for severe aortic regurgitation is limited due to the risk of insufficient anchoring of the valve stent w...
متن کاملConcomitant Transapical Transcatheter Valve Implantations: Edwards Sapien Valve for Severe Mitral Regurgitation in a Patient with Failing Mitral Bioprostheses and JenaValve for the Treatment of Pure Aortic Regurgitation.
Transcatheter valve implantation is a novel interventional technique, which was developed as an alternative therapy for surgical aortic valve replacement in inoperable patients with severe aortic stenosis. Despite limited experience in using transcatheter valve implantation for mitral and aortic regurgitation, transapical transcatheter aortic valve implantation and valve-in-valve implantation ...
متن کاملTransapical aortic valve implantation using a Symetis Acurate self-expandable bioprosthesis: initial outcomes of 10 patients
INTRODUCTION Transapical aortic valve implantation (TA-AVI) has been widely introduced for treatment of patients with severe aortic stenosis in the last decade. Here we report our first clinical experience with 10 patients using the second-generation transapical Symetis Acurate TA aortic valve designed for transapical implantation. AIM To evaluate the results of transapical access in transcat...
متن کاملTransapical aortic valve implantation in patients with previous cardiac surgery.
BACKGROUND This study compared surgical outcomes of patients with previous cardiac surgery undergoing transapical transcatheter aortic valve implantation (PCS-TA-TAVI) with those of patients undergoing transapical transcatheter aortic valve implantation as an initial procedure (initial TA-TAVI) by using propensity analysis. METHODS From January 2005 through January 2013, 267 consecutive high-...
متن کاملTransapical approach for transcatheter aortic valve implantation.
With the advancement of device technology and procedural techniques, most transcatheter aortic valve implantation (TAVI) procedures have been performed with the transfemoral approach in recent years (1). However, alternative approaches such as transapical, trans-subclavian, direct aortic and others still play an important role in patients with poor vascular access. Transapical approach is the o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- European heart journal
دوره 32 18 شماره
صفحات -
تاریخ انتشار 2011